GSK has moved a step closer to approval of its cancer immunotherapy Jemperli as a first-line treatment for endometrial cancer in the EU. The EMA has started its review of the PD-1 inhibitor in ...

That’s important for GSK, as Jemperli is currently approved as a first-line therapy for use in endometrial cancer patients whose tumours have mismatch repair deficient (dMMR) or microsatellite ...

FDA approval for Jemperli plus chemotherapy was expanded to include all adult patients with primary advanced or recurrent endometrial cancer in August 2024. More on GSK GSK plc (GSK) 43rd Annual J ...

Also, treatment with Jemperli plus chemotherapy demonstrated a median OS of 44.6 months compared with 28.2 months for chemotherapy alone. Jemperli was approved for similar expanded use in ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix for the prevention of shingles.

The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI , an oral, once-daily ...